Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves FoundationOne CDx for Takeda's ALK-Inhibitor

NEW YORK – Foundation Medicine said on Thursday that the US Food and Drug Administration has approved the company's tissue-based, next-generation sequencing test, FoundationOne CDx, as a companion diagnostic for Takeda's FDA-approved non-small cell lung cancer treatment brigatinib (Alunbrig).

The approval comes after Roche subsidiary Foundation Medicine and Takeda inked a deal last year to develop companion diagnostics for Takeda's NSCLC agents. Brigatinib has been FDA-approved to treat ALK-positive NSCLC patients who are refractory to crizotinib (Pfizer's Xalkori) since 2017, and it is approved as a first-line treatment for ALK-positive NSCLC since last year. At the time of brigatinib's first-line FDA approval, the agency approved Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit as a companion diagnostic.

FDA's decision to approve FoundationOne CDx as a companion diagnostic for brigatinib, according to Foundation Medicine, reflects a recognition that ALK rearrangements can be overlooked with alternative non-NGS testing methods. FoundationOne CDx, which detects substitutions, insertion and deletion alterations, copy number alterations in 324 genes, and select gene rearrangements, now has a total of 28 companion diagnostic claims.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.